Dr. Reddy’s Laboratories (DRREDDY) 52 Week High Streak: Second Straight Session Near Peak
- November 19, 2026
- Posted by: Chaitanya Auti
- Category: News
Dr. Reddy’s Laboratories Ltd. (DRREDDY) has now traded within 2% of its 52-week high for its second straight session, and the stock has moved 0.22% across that streak. As of 19 November 2026 at 9:22 AM IST, the share price was Rs 1,390.05 after touching a high of Rs 1,403.65 earlier in the session. Latest Univest data confirms the repeated-high pattern, but it does not establish a company-specific catalyst behind the continued move.
The stock last traded below its previous close of Rs 1,396 and opened at the same level, with the intraday low at Rs 1,390. The company’s market capitalisation stands at Rs 1,15,852.16 crore. For readers, the key point is not just the day’s move but the persistence of trading close to a one-year peak across more than one session, which places the stock in a different category from a one-day spike.
Dr. Reddy’s Laboratories 52 Week High Streak: Consecutive High Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 1,390.05 |
| Previous Close | Rs 1,396 |
| Today's Move | Rs -5.95 (-0.43%) |
| Open | Rs 1,396 |
| High | Rs 1,403.65 |
| Low | Rs 1,390 |
| Market Capitalisation | Rs 1,15,852.16 crore |
Dr. Reddy's Laboratories Ltd. (DRREDDY) traded at Rs 1,390.05 versus the previous close of Rs 1,396, a fall of 0.43%. The stock opened at Rs 1,396, reached a high of Rs 1,403.65 and touched a low of Rs 1,390.
Dr. Reddy’s Laboratories share price today moved within a narrow band around the opening print, with the stock trading at Rs 1,390.05, down Rs 5.95 or 0.43% from the previous close of Rs 1,396. The day started at Rs 1,396, moved to a high of Rs 1,403.65, and touched a low of Rs 1,390. The current price is near the lower end of that range, but it remains close to the one-year high zone that has kept the stock in focus for a second straight session.
The market capitalisation of Rs 1,15,852.16 crore places Dr. Reddy’s Laboratories among the larger listed names in the pharmaceuticals space. For readers tracking the stock price today, the immediate takeaway is that the share price has not drifted far from its recent peak area, even though the session itself shows a mild decline. In other words, the move is less about a fresh breakout narrative and more about the stock holding near elevated levels across consecutive sessions. That is why the Dr. Reddy’s Laboratories 52 Week High Streak matters as a separate pattern from a single-day headline.
What the Repeated 52-Week Highs Show
The repeated 52-week high pattern suggests that Dr. Reddy’s Laboratories has stayed close to its yearly high without a confirmed company-specific trigger in the latest Univest data. Over two sessions, the cumulative streak move has been 0.22%, which is modest, but it still matters because it shows that the stock has remained in the upper part of its recent trading band instead of quickly fading away after the first move.
That distinction is important for anyone following a 52 week high streak. A single session near the high can be a short-lived price event. A second straight session near the same area tells investors that the market has continued to keep the stock in sight, even though the data does not assign a reason for that persistence. The current pattern can therefore be read as a repeated-high setup rather than a one-day event, and it is best understood through the full streak move, not just the latest print.
For search intent around Dr. Reddy’s Laboratories 52 Week High Streak, the practical question is whether the stock is simply lingering near the peak or moving into a more durable higher range. The latest price pattern only confirms the former on a factual basis. It does not justify any stronger claim about why the move is happening or how far it might extend.
Dr. Reddy's Laboratories Ltd. (DRREDDY) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 1,15,852.16 crore |
| P/E Ratio | 41.65x |
| P/B Ratio | 3x |
| ROE | 11.69% |
| ROCE | 13.75% |
| EPS | Rs 33.52 |
| Book Value Per Share | Rs 464.6 |
| Dividend Yield | 0.57% |
Dr. Reddy's Laboratories Ltd. (DRREDDY) fundamental metrics show P/E 41.65x, P/B 3x, ROE 11.69%, ROCE 13.75%. These figures provide context only and are not a buy or sell signal.
Dr. Reddy’s Laboratories Ltd. has a market capitalisation of Rs 1,15,852.16 crore, which gives readers a sense of company size before judging valuation. On valuation, P/E at 41.65x, P/B at 3x should be read against the sector and peer benchmarks rather than as a standalone signal. Profitability is represented by ROE of 11.69% and ROCE of 13.75%, helping investors compare shareholder returns and capital efficiency. According to latest Univest data, additional metrics include EPS of Rs 33.52, book value per share of Rs 464.6, dividend yield of 0.57%, adding context to earnings, balance-sheet value and historical payout. Against the latest Univest same industry benchmark, these figures can be compared with benchmark median P/E of 26.53x, median ROE of 10.98%, median ROCE of 12.76%. These numbers explain the fundamental backdrop without converting the article into a buy or sell view.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Industry | Pharmaceuticals & Drugs |
| Benchmark Scope | same industry |
| Company P/E Ratio | 41.65x |
| Benchmark Median P/E | 26.53x |
| Benchmark Average P/E | 51.02x |
| Benchmark P/E Range | 0x to 1,378.1x |
| Company P/B Ratio | 3x |
| Benchmark Median P/B | 2.78x |
| Company ROE | 11.69% |
| Benchmark Median ROE | 10.98% |
| Company ROCE | 13.75% |
| Benchmark Median ROCE | 12.76% |
| Company Market Capitalisation | Rs 1,15,852.16 crore |
| Benchmark Median Market Cap | Rs 789.38 crore |
Dr. Reddy's Laboratories Ltd. (DRREDDY) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.
Dr. Reddy's Laboratories Ltd. (DRREDDY) has a P/E ratio of 41.65x, which is above the benchmark median of 26.53x, a difference of +56.99%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Dr. Reddy's Laboratories Ltd. (DRREDDY) has a ROE of 11.69%, which is above the benchmark median of 10.98%, a difference of +6.47%. Dr. Reddy's Laboratories Ltd. (DRREDDY) has a ROCE of 13.75%, which is above the benchmark median of 12.76%, a difference of +7.76%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Zydus Lifesciences Ltd. | ZYDUSLIFE | 1,19,969.79 | 28.52 | 4.29 | 19.69 | 21.39 |
| Cipla Ltd. | CIPLA | 1,11,730.92 | 39.6 | 3.24 | 11.83 | 16 |
| Mankind Pharma Ltd. | MANKIND | 1,07,612.7 | 48.62 | 6.2 | 12.69 | 13.24 |
| Laurus Labs Ltd. | LAURUSLABS | 1,26,433.06 | 93.64 | 20.7 | 18.31 | 18.2 |
| Aurobindo Pharma Ltd. | AUROPHARMA | 1,03,145.12 | 25.97 | 2.63 | 9.93 | 12.76 |
Dr. Reddy's Laboratories Ltd. (DRREDDY) has a P/E ratio of 41.65x compared with the displayed peer median of 39.6x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 11.69% compares with a peer median of 12.69% across the companies shown in the table. ROCE stood at 13.75% versus the displayed peer median of 16%, providing a capital-efficiency comparison. Dr. Reddy's Laboratories Ltd. (DRREDDY) has a market capitalisation of Rs 1,15,852.16 crore. Among the 5 peers shown, 2 have a larger market capitalisation.
Why Investors Are Watching Dr. Reddy’s Laboratories
- The stock has traded within 2% of its 52-week high for a second straight session, keeping the Dr. Reddy’s Laboratories 52 Week High Streak in focus.
- Its cumulative move across the streak is 0.22%, which gives a clearer view of the pattern than a single-session move.
- The share price was Rs 1,390.05 as of 19 November 2026 at 9:22 AM IST, with the day’s high at Rs 1,403.65.
- The company’s market capitalisation is Rs 1,15,852.16 crore, keeping it among the larger names in the healthcare space.
- Valuation remains above the industry median, so the stock continues to attract interest from a stock analysis and fundamental analysis perspective.
About Dr. Reddy’s Laboratories
Dr. Reddy’s Laboratories Ltd. is a listed pharmaceuticals company on NSE and BSE within the healthcare sector. The business operates in the pharmaceuticals and drugs industry, where investors typically follow company financials, product execution, pricing trends and relative valuation. Its market capitalisation of Rs 1,15,852.16 crore places it among the more valuable names in the domestic pharma space.
For readers following Dr. Reddy’s Laboratories stock performance, the current discussion is less about a single trading session and more about the stock holding near a one-year high for multiple sessions. That is why the 52 week high streak matters alongside the broader company fundamentals.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Uniresearch Global Pvt. Ltd. (Research Analyst, SEBI Registration Number INH000013776), a subsidiary of Univest Communication Technologies Private Limited.
Frequently Asked Questions
Why is Dr. Reddy's Laboratories in the news today?
Ans. Dr. Reddy's Laboratories is in focus because it has traded within 2% of its 52-week high for a second straight session. The latest price action keeps the stock on the radar for readers tracking 52 week high stocks and company news.
What does the Dr. Reddy's Laboratories 52 Week High Streak mean?
Ans. It means the stock has stayed close to its one-year high for two consecutive sessions. That pattern is different from a one-day spike because it shows repeated trading near the upper end of the recent range.
How much has Dr. Reddy's Laboratories moved across the streak?
Ans. The cumulative move across the streak is 0.22%. That figure captures the full repeated-high pattern better than looking only at the latest change on one trading day.
Did the latest data confirm a company-specific catalyst?
Ans. No. The latest Univest data confirms the price pattern, but it does not establish a company-specific catalyst behind the continued move. Investors should treat the streak as a market observation rather than a proven event driver.
Is Dr. Reddy's Laboratories expensive compared with peers?
Ans. The stock trades at a P/E of 41.65, which is above the industry median of 26.53 and above some peers, though below others such as Mankind Pharma and Laurus Labs. It therefore sits in a premium valuation band.
How do the fundamentals look for Dr. Reddy's Laboratories?
Ans. The company shows ROE of 11.69% and ROCE of 13.75%, with EPS of Rs 33.52 and book value of Rs 464.6. Those figures suggest reasonable profitability, although the valuation remains ahead of the sector median.
What should investors watch next in Dr. Reddy's Laboratories?
Ans. Investors should monitor whether the stock continues to trade near its yearly high, whether the repeated-high pattern persists, and how valuation compares with earnings delivery. The next update will matter most if it changes the streak or the fundamental backdrop.
Track Dr. Reddy's Laboratories Ltd. (DRREDDY) Share Price on Univest
Use Dr. Reddy's Laboratories Ltd. (DRREDDY) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.